DelveInsight’s Systemic Lupus Erythematosus Market Insightsreport includes a comprehensive understanding of current treatment practices, emerging systemic lupus erythematosus drugs, market share of ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

New findings from a Phase II study indicate that antenatal treatment with the FcRn blocker nipocalimab resulted in low fetal drug exposure and transient reductions in infant IgG levels at birth, ...

Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...

In patients with systemic lupus erythematosus, impaired upper limb function and difficulty performing daily activities are linked to various quality-of-life domains.

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...

In a new study, researchers looked to identify unique biomarkers and shared microbial mechanisms among different autoimmune diseases and found that the gut microbiome plays a critical role. Systemic ...

Researchers explored the connection between systemic lupus erythematosus (SLE) and thyroid (a gland in the body that produces hormones regulating metabolism and growth) disorders and report a complex ...